Post by Hot Christian Stocks on Jul 23, 2014 22:17:59 GMT -5
Introducing
Cannabis Science, Inc.
(CBIS)
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.
Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.
We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are GMP compliant, surpassing high quality standard industrial and food processing requirements.
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses.
Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.
CS-S/BCC1 is in preparation to enter phase I clinical trials within one to two year. This product is formulated for topical administration to be tested in phase I study, with an indication for skin cancer.
CS-TATI1 is in preclinical development with the indication for infectious disease. Consistent with data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2) which has potential applications in HIV and other infectious diseases.
In 2013, Cannabis Science submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety. The first formulation in the series of neurobehavioral disorder-targeted products is the pre-clinical development and use of the invention in food products through a licensing agreement with partner company, ENDOCAN Corporation, Inc. And Cannabis Science will move forward at the same time with pharmaceutical grade development.
Basis & Philosophy
Cannabis plants have extensive history of medical and agricultural use dating back thousands of years. To date hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.
Some key phytocannabinoids are:
• tetrahydrocannabinol (THC)
• cannabidiol (CBD)
• cannabigerol (CBG)
• cannabichromene (CBC)
• cannabinol (CBN)
These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC. Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.
The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.
Cannabis Science is developing novel cannabis based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.
The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.
The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.
While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients’ lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.
These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.
As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire "seed to sale" process with a focus on bio-pharmaceutical development.
Cannabis Science is one of the longest standing companies in the cannabis business.
We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions. Scientifically, we know this is the beginning of one of the greatest expansions of medicine and industry we will ever experience in our lifetime.
Cannabis Science, Inc. is a patient oriented company dedicated to meeting the needs of the community with products based on cannabinoid science, as well as being an advocate for patient rights throughout the world.
What We Do
At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.
Our pursuit of knowledge is done creatively and diligently. Our team of bright minds is always at work to undertake groundbreaking research, and use it to devise new, innovative, and exciting projects, such as medications that can save lives and change a patient’s way of life for the better, and expanding globally so that our positive influence reaches across borders.
The Science of Cannabinoids
Cannabinoids have an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis.
Pipeline
See what Cannabis Science has in the works and their progress. These programs will change the lives of many people of all ages, shapes, and sizes, with a variety of illnesses that cannabinoid-based medications can target. These illnesses include cancer, HIV/AIDS, arthritis, chronic pain, and a myriad of others. Click here to see what’s coming down the pipeline!
Monday, July 21, 2014
• Best marijuana stocks to buy nowat MarketWatch (Mon, Jul 21)
Friday, July 18, 2014
• CFO Journal, part of the Wall Street Journal, addresses business challenges of cannabis industry in the article "Pot Industry Puts on a Tie" referencing Cannabis Science, Inc. (CBIS) Chief Financial Officer, Robert KanePR Newswire (Fri, Jul 18)
Thursday, July 17, 2014
• Cannabis Capital Corp. (CBCA) Changes Name to Crown Baus Capital Corp., Better Reflecting Corporate Initiatives and Long-term ProjectsPR Newswire (Thu, Jul 17)
Tuesday, July 15, 2014
• Looking at Cannabis Therapy’s Multi-Pronged Approach to CommercializationAccesswire (Tue, Jul 15)
Tuesday, July 8, 2014
• Cannabis Science, Inc. (CBIS) Prepares for New York State as it becomes the 23rd state to authorize Medical Marijuana usePR Newswire (Tue, Jul 8)
Thursday, June 26, 2014
• CBCA Subsidiary, WebCongress, Inc. is Proud to be an Official Live Stream Host of the Google I/O Developer Conference Underway June 25-26 in Miami, As Well, Live Stream is Available Globally via Click here PR Newswire (Thu, Jun 26)
Monday, June 23, 2014
• Cannabis Therapy Uses Hemp to Shorten Time to MarketAccesswire (Mon, Jun 23)
Wednesday, June 18, 2014
• Cannabis Therapy Pursues IP Strategy in Cannabis IndustryAccesswire (Wed, Jun 18)
Monday, June 16, 2014
• Cannabis Capital Corp. (CBCA) and WebCongress Getting In On Ground Floor of Google Inc. (GOOG)-Based TechnologiesAccesswire (Mon, Jun 16)
Wednesday, June 11, 2014
• CANNABIS SCIENCE, INC. FinancialsEDGAR Online Financials (Wed, Jun 11)
Tuesday, June 10, 2014
• Cannabis Therapy Targets Low-Hanging Fruit with Experienced TeamAccesswire (Tue, Jun 10)
Friday, June 6, 2014
• Government Pot Contract Open for Bids, but Nobody Wants Itat TheStreet (Fri, Jun 6)
• Dow, S&P Both Jump to Record Highs - Will Congress Decision Impact Marijuana Index?Accesswire (Fri, Jun 6)
Thursday, June 5, 2014
• Cannabis Science, Inc. (CBIS) Reports Strongest Financial Position in its History, Citing Filings & Financial Statements as the Company Moves Forward with Multiple Cannabis Drug Development ProgramsPR Newswire (Thu, Jun 5)
Wednesday, June 4, 2014
• CANNABIS SCIENCE, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online (Wed, Jun 4)
Tuesday, June 3, 2014
• CBIS Reports on CBS News; Historic Marijuana Vote from United States House of Representatives Creates Serious Confidence as Marijuana Wins U.S. House Vote for First Time in HistoryPR Newswire (Tue, Jun 3)
Monday, June 2, 2014
• CANNABIS SCIENCE, INC. Files SEC form 8-K, Changes in Control or Registrant, Change in Directors or Principal OfficerEDGAR Online (Mon, Jun 2)
• Cannabis Science Operational Update: First Data from Preclinical Development Expected This Week; Cannabis Science Plans to Open Informational Hotline for General PublicPR Newswire (Mon, Jun 2)
Tuesday, May 27, 2014
• Cannabis Science Cheers Dr. Oz on Becoming a Vocal Supporter of Medical Marijuana on The Larry King Live ShowPR Newswire (Tue, May 27)
• Cannabis Science Inc. Moves Forward with MEDIWIET Preparing Observational Study in the NetherlandsPR Newswire (Tue, May 27)
Thursday, May 22, 2014
• Cannabis Science Issues CBN Patent and R&D Progress Guidance for the 2nd Quarter of 2014PR Newswire (Thu, May 22)
Thursday, May 15, 2014
• New Colombia Resources Inc. Enters Into a Collaboration Agreement With Farmatech S.A. for Research and Development of Topical Cannabis Based Medicines in ColombiaPR Newswire (Thu, May 15)
Friday, May 9, 2014
• New Colombia Resources Inc. Enters into a Collaboration Agreement with the Phoenix Tears Foundation for Research and Development of a Cannabis Based Medicine to Treat Skin Cancer in Colombia.PR Newswire (Fri, May 9)
Tuesday, May 6, 2014
• BreedIT Corp: The Money is in the SeedsAccesswire (Tue, May 6)
Thursday, May 1, 2014
• Investors high on marijuana despite risksat CNNMoney.com (Thu, May 1)
Disclaimer: pennystockdivas.com is wholly owned by Global Innovator Relations LLC. This email and the content provided is intended for advertisement purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our e-mail list. PLEASE NOTE: Global Innovator Relations, LLC and pennystockdivas.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at pennystockdivas.com/disclaimer Release of Liability: Through use of this website/newsletter viewing or using you agree to hold pennystockdivas.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Pennystockdivas.com’s affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Pennystockdivas.com encourages readers and investors to supplement the information in these reports with independent research and other pro advice. All information on featured companies is provided by the companies profiled, or is available from public sources and pennystockdivas.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Pennystockdivas.com often receives compensation for marketing, awareness and investor relation services, which can be reviewed within our disclaimer. Pennystockdivas.com has been compensated $1000 cash for the release of this newsletter and or other marketing services by Microcao Innovations a non controlling third party. Pennystockdivas.com, Global Innovator Relations, LLC nor any of its affiliates are not registered investment advisors or broker dealers.